Posted 6 days ago

A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/​Metastatic Head and Neck Cancer (OrigAMI-5)

ClinicalTrials.gov ID NCT07276399

Protocol number 61186372HNC3001

Sponsor Janssen Research & Development, LLC